

PATROCINADORES

LICENSED BY



AVALADO POR:



Consejo Mexicano  
de Ginecología y  
Obstetricia A.C.

P R O G R A M A

**MIÉRCOLES 6 DE MARZO**

7:50 a 8:50

**Registro e Inscripciones**

HORARIO	TEMA	PONENTE
08:00	<b>Desayuno con experto Agefinsa</b> <b>Uso de Ácido Tranexámico en Cirugía Oncológica</b>	<b>Dra. Nadia Reyes Aparicio</b>
9:00	<b>INAUGURACIÓN</b>	<b>Maestro de Ceremonias:</b> <b>Dra. Eva Ruvalcaba Limón</b>
09:30	GS01-01 Biomarker Results in High-risk Estrogen Receptor Positive, Human Epidermal Growth Factor Receptor2 Negative Primary Breast Cancer Following Neoadjuvant Chemotherapy ± Nivolumab:an Exploratory Analysis of CheckMate 7FL	<b>Dra. Connie Zuratzi Deneken Hernández</b>
09:45	GS03-03 Ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) as adjuvant treatment in patients with HR+/HER2- early breast cancer: final invasive disease-free survival (iDFS) analysis from the NATALEE trial	<b>Dra. Perla Pérez Pérez</b>
10:00	<b>P A N E L D E D I S C U S I Ó N</b>	<b>Dra. Guadalupe Cervantes Sánchez</b>
10:20	GS02-01 Randomised phase 3 study of datopotamab deruxtecan vs chemotherapy for patients with inoperable or metastatic hormone receptor-positive, HER2- breast cancer: efficacy, safety and biomarker results from TROPION-Breast01.	<b>Dra. Rosa Elena Caballero Landinez</b>
10:35	GS01-12 MONARCH 3: Final overall survival results of abemaciclib plus a nonsteroidal aromatase inhibitor as first-line therapy for HR+, HER2- advanced breast cancer	<b>Dr. Hugo Alberto Millán Aguilar</b>
10:50	<b>P A N E L D E D I S C U S I Ó N</b>	<b>Dra. Zuleyma Nieto García</b>
11:10	<b>SIMPOSIUM Chicago University,</b> <b>Current and emerging therapies for triple negative Breast Cancer</b>	<b>Dra. Rita Nanda</b>
12:00	<b>R E C E S O</b>	
12:20	<b>SIMPOSIUM Chicago University</b> <b>Cirugía Oncoplástica de la mama e introducción de la técnica simplificada MOLLER y sus resultados clinicos</b>	<b>Dra. Mecker G. Möller</b>
13:10	PS10-01 Hormonal Contraception and Breast Cancer Risk for Carriers of Germline Pathogenic Variants in BRCA1 and BRCA2 PS13-01 Worse Prognosis for Breast Cancer in the Second and Third Trimesters and Shortly Postpartum: An Update of the Dutch Pregnancy-Associated Breast Cancer Cohort	<b>Dra. Mónica Alejandra Matta Martínez</b>
13:25	GS02-11 Fertility preservation and assisted reproductive technologies (ART) in breast cancer (BC) patients (pts) interrupting endocrine therapy (ET) to attempt pregnancy	<b>Dr. Jorge Alberto Campos Caña</b>
13:40	GS02-10 Effects of a structured and individualized exercise program on fatigue and health-related quality of life in patients with metastatic breast cancer: the multinational randomized controlled PREFERABLE-EFFECT study	<b>Dra. Naxiely Audelia Santiago Sampé</b>
13:55	<b>P A N E L D E D I S C U S I Ó N</b>	<b>Dra. Eva Ruvalcaba Limón</b>
14:20	<b>C I E R R E D E L D Í A</b>	

PATROCINADORES

LICENSED BY  
**ENCORE**  
MEDICAL EDUCATION

AVALADO POR:

**CMO**  
Consejo Mexicano de Oncología

Consejo Mexicano  
de Ginecología y  
Obstetricia A.C.

**P R O G R A M A**

**JUEVES 7 DE MARZO**

7:50 a 8:50

**Registro e Inscripciones**

**HORARIO**

**TEMA**

**PONENTE**

HORARIO	TEMA	PONENTE
08:00	<b>Desayuno con experto Stendhal</b> <b>El Impacto de la Náusea y el Vómito en las Terapias ADC</b>	<b>Dr. Roberto Iván Sánchez Reyes</b>
09:00	<b>P R E S E N T A C I Ó N D E L D Í A</b>	<b>Maestro de Ceremonias</b> <b>Dr. Pabel Miranda Aguirre</b>
09:10	GS02-02 Are Nodal ITCs after neoadjuvant chemotherapy and indication for axillary dissection? The OPBC05/EUBREAST-14R/ICARO study.	<b>Dr. Rafael Vázquez Romo</b>
09:25	Surgery GS02-04 Surgical Treatment of Women with Breast Cancer and a BRCA1 Mutation: An International Analysis of the Impact of Bilateral Mastectomy on Survival	<b>Dr. Juan Alberto Tenorio Torres</b>
09:40	<b>P A N E L D E D I S C U S I Ó N</b>	<b>Dr. Jorge Enrique Monges Jones</b>
10:00	Radiotherapy GS02-07 Loco-Regional Irradiation in Patients with Biopsy-proven Axillary Node Involvement at Presentation Who Become Pathologically Node-negative After Neoadjuvant Chemotherapy: Primary Outcomes of NRG Oncology/NSABP B-51/RTOG 1304	<b>Dr. Daniel Rivera Sánchez</b>
10:15	GS02-08 Five-year outcomes of the IDEA trial of endocrine therapy without radiotherapy after breast-conserving surgery for postmenopausal patients age 50-69 with genomically-selected favorable Stage I breast cancer	<b>Dr. Adolfo Fernández Díaz</b>
10:30	<b>P A N E L D E D I S C U S I Ó N</b>	<b>Dr. Jorge Anselmo Vázquez Delgado</b>
10:50	<b>SIMPOSIUM South Genetics</b> <b>Cambiamos la historia del Cáncer de Mama,</b> <b>Usemos OncotypeDx</b>	<b>Dra. Carolina Blanco</b>
11:40	<b>R E C E S O</b>	
12:00	<b>SIMPOSIUM ROCHE,</b> <b>Avances en el tratamiento del Cáncer de Mama temprano</b> <b>Her2 positivo con enfermedad residual</b>	<b>Dra. Diana Fabiola Flores Díaz</b> (presencial)
12:50	Her2 Positive GS01-10 HER2CLIMB-02: Randomized, Double-Blind Phase 3 Trial of Tucatinib and Trastuzumab Emtansine for Previously Treated HER2-Positive Metastatic Breast Cancer	<b>Dra. María del Mar García Ortega</b>
13:05	Her2 Positive GS03-12 Phase III study of adjuvant ado-trastuzumab etamsine vs trastuzumab for residual invasive HER2-positive early breast cancer after neoadjuvant chemotherapy and HER2-targeted therapy: KATHERINE final IDFS and updated OS analysis	<b>Dr. Salvador González Santiesteban</b>
13:20	<b>P A N E L D E D I S C U S I Ó N</b>	<b>Dra. Claudia Haydée Arce Salinas</b>
13:40	<b>C I E R R E D E L D Í A</b>	

PATROCINADORES

LICENSED BY



AVALADO POR:



Consejo Mexicano  
de Ginecología y  
Obstetricia A.C.

P R O G R A M A

**VIERNES 8 DE MARZO**

7:50 a 8:50

**Registro e Inscripciones**

HORARIO	TEMA	PONENTE
08:00	<b>Desayuno con experto de La Roche Posay</b> <b>Tratamiento de reacciones adversas por terapias oncológicas</b>	<b>Dra. Lizette Arizmendi</b>
09:00	<b>P R E S E N T A C I Ó N D E L D Í A</b>	<b>Maestro de Ceremonias</b> <b>Dra. Betsabé Hernández Hernández</b>
09:10	GS01-05 Pembrolizumab + Olaparib vs Pembrolizumab + Chemotherapy after induction with Pembrolizumab + Chemotherapy for locally recurrent inoperable or Metastatic TNBC: Randomized Open-Label Phase 2 KEYLYNK-009 Study	<b>Dra. Rocío Crystal Grajales Álvarez</b>
09:25	GS01-03 Adding Atezolizumab to adjuvant chemotherapy for stage II and III triple negative breast cancer in unlikely to improve efficacy interim analysis of the ALEXANDRA/Impassion030 phase 3 trial.	<b>Dr. Abraham Ruiz García</b>
09:40	<b>P A N E L D E D I S C U S I Ó N</b>	<b>Dra. Flavia Morales Vásquez</b>
10:00	GS03-06 Genomic and transcriptomic profiling of primary tumors from patients with HR+, HER2-, node-positive, high-risk early breast cancer in the monarchE trial	<b>Dra. Sandra Lorena Romero Córdoba</b>
10:15	GS03-07 Protocol-defined biomarker analysis in the PALLAS (AFT-05) adjuvant trial: Genomic subtype derived from RNA sequencing of HR+/HER2- early breast cancer	<b>Dra. Bertha Alejandra Martínez Cannon</b>
10:30	GS01-02 Phase 3 study neoadjuvant pembrolizumab or placebo plus chemotherapy, followed by adjuvant pembrolizumab or placebo plus endocrine therapy for early-stage high-risk ER+/HER2- BC: KEYNOTE-756	<b>Dr. Santiago Alejandro Cano Cancela</b>
10:45	<b>P A N E L D E D I S C U S I Ó N</b>	<b>Dra. Paula Anel Cabrera Galeana</b>
11:10	<b>SIMPOSIUM AstraZeneca OlympiA,</b> <b>Identificación y manejo oportuno de Cáncer de Mama temprano gBRCAm</b>	<b>Dra. Alexandra Garcilazo</b>
12:00	<b>R E C E S O</b>	
12:20	<b>SIMPOSIUM AstraZeneca DB04,</b> <b>Nuevos paradigmas en Cáncer de Mama HER2-low y utilidad de Trastuzumab-deruxtecan</b>	<b>Dra. Georgina Garnica</b>
13:00	GS02-05 Overview of Axillary Treatment in Early Breast Cancer: patient-level meta-analysis of long-term outcomes among 20,273 women in 29 randomised trials	<b>Dr. Carlos Fernando Gómez Cuevas</b>
13:15	GS02-06 Recurrence-free survival following sentinel node-positive breast cancer without completion axillary lymph node dissection – first results from the international randomized SENOMAC trial.	<b>Dr. Felipe Villegas Carlos</b>
13:30	PS01-10 Surgical margins in breast conserving surgery for DCIS and clinical outcomes: significant associations with increased recurrence and OS. PS01-06 The relationship between margin status of <2mm and local recurrence in DCIS patients	<b>Dr. Arturo Pabel Miranda Aguirre</b>
13:45	<b>P A N E L D E D I S C U S I Ó N</b>	<b>Dr. Gregorio Quintero Beuló</b>
14:00	<b>C L A U S U R A</b>	